A prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled Tobramycin in patients with ventilator-associated pneumonia (iToVAP)
Authors' conclusion
Inhaled aerosolized Tobramycin demonstrated clinically meaningful efficacy in patients with Gram-negative ventilator-associated pneumonia.
Study context
- Population
- ICU patients with VAP caused by Gram-negative pathogens
- Participants
- 26 patients
- Comparison
- Tobramycin Inhal vs Control
- Tobramycin Inhaln = 14
- Controln = 12reference
Methodological detailsprospective, multicentre, double-blinded, placebo-controlled, phase IIA
- Prospective
- Multicentre
- Double-blinded
- Placebo-controlled
- Phase IIA
Primary result
As reported in the abstract
Probability of eradication
P < 0.001
Further findings
Survival
- Increased eradication not associated with increased survival
Systemic anti-infective therapy and ICU stay
- Eradication not associated with reduced systemic anti-infective therapy or shorter ICU stay
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
A prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled Tobramycin in patients with ventilator-associated pneumonia (iToVAP). Anaesth Crit Care Pain Med. Published 20 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →